Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox™ technology platform.

About Rakuten Medical, Inc.			
Company Name	Rakuten Medical, Inc.		
Co-CEO	Hiroshi Mikitani, Takashi Toraishi		
Office Location	Rakuten Medical, Inc.	San Diego, USA	Corporate and R&D HQ
Subsidiaries	Rakuten Medical K.K.	Tokyo, Japan	Asia Operations and Device R&D
	Rakuten Medical Europe, B.V.	Amsterdam, Netherlands	Europe Operations and Device Oversight
	Rakuten Medical Taiwan, Inc.[1)]	Taipei, Taiwan	Development and Operations in Taiwan
	Rakuten Medical Private Limited	Mumbai, India	Development and Operations in India
	Medlight SA[2)]	Ecublens, Switzerland	Device Development and Manufacturing
Founded	2010 (Aspyrian Therapeutics, Inc.)		
Business	Development, manufacturing and commercialization of drug and medical devices		
Employees	Approx. 200 (Including subsidiaries. As of December 2022)		

[1)] Rakuten Medical Taiwan Inc. is a subsidiary of Rakuten Medial Japan K.K.
[2)] Medlight SA is an indirect wholly owned subsidiary of Rakuten Medical Inc.

History		
2010	Apr	Founding of Aspyrian Therapeutics, Inc. in San Diego, California, U.S
2011	Nov	Dr. Hisataka Kobayashi of the U.S. National Cancer Institute published a paper on photoimmunotherapy, the technology underlying Alluminox™ platform, in the journal, Nature Medicine
2013	Apr	Mickey was investor for Aspyrian Therapeutics, Inc.
	Sep	Aspyrian Therapeutics, Inc. granted an exclusive license from the National Institutes of Health to develop and commercialize photoimmunotherapy
2015	Jun	Initiation of Phase 1/2a trial (ASP-1929-101) to evaluate RM-1929* in recurrent head and neck squamous cell carcinoma (rHNSCC) in U.S.
2017	Mar	Office opened in Tokyo, Japan
2018	Jan	Fast Track designation of RM-1929* in rHNSCC by Food and Drug Administration (FDA)
	Mar	Initiation of Phase 1 trial (ASP-1929-102) to evaluate RM-1929* in rHNSCC in Japan
	Nov	Hiroshi Mikitani appointed as CEO
2019	Mar	Rebranded company name to Rakuten Medical, Inc.
	Apr	ASP-1929 in HNC received Sakigake designation by Min. of Health, Labour and Welfare (MHLW) in Japan
	May	Office opened in Taipei, Taiwan
	May	Initiation of Global Phase 3 trial (ASP-1929-301) to evaluate ASP-1929 in rHNSCC
	Jul	Office opened in Amsterdam, Netherlands
2020	Mar	Submitted a Japanese Biological License Application (JBLA) for ASP-1929 under the Conditional Early approval System (CEAS) and applied for Japan approval of the laser illumination system
	May	Alluminox™ Alliance Institutes (AAI) agreement with The National Cancer Center Japan

	Jun	Strategic alliance collaboration agreement with The University of Texas MD Anderson Cancer Center to advance Alluminox™ platform for cancer treatments
	Jul	Multi-year agreement with Merck KGaA to receive cetuximab for production of ASP-1929
	Aug	The acquisition of Medlight SA
	Sep	Received marketing approval from MHLW for Rakuten Medical's first drug, Akalux® IV Infusion 250mg and medical device, BioBlade® Laser System
	Dec	Initiation of phase 1b/2 trial (ASP-1929-181) to evaluate ASP-1929 in combination with anti-PD1 therapy in HNSCC or cuSCC
2021	Jan	Commercialization of Akalux® IV Infusion 250mg and BioBlade® Laser System in Japan
	Jan	Acquired phthalocyanine dyes, including IRDye® 700DX, from LI-COR Biosciences
	Jun	Joint development and commercialization agreement with Shimadzu Corporation to advance a medical device for use on the Alluminox™ platform
	Oct	Strategic partnership with Karkinos Healthcare to expand the reach of novel cancer care in India
	Dec	IND for RM1995 in advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma
2022	Jan	Initiation of Phase 2 trial (ASP1929-103) to evaluate ASP-1929 administered prior to standard of care surgical tumor resection in patients with operable primary or recurrent HNSCC or cuSCC
	Apr	Initiation of a phase 2 trial (ASP1929-218) to evaluate ASP-1929 with pembrolizumab in patients with locoregional recurrent HNSCC, with or without metastases, not amenable to curative local treatment
	Apr	Office opened in Mumbai, India

*RM-1929 and ASP-1929 are analogous. Extensive physiochemical studies show that they have comparable physical and chemical properties.

(As of December 2022)